How Tigecycline Affects Liver Enzymes
Tigecycline, a glycylcycline antibiotic, can elevate liver enzymes like ALT, AST, alkaline phosphatase, and bilirubin, signaling potential hepatotoxicity. These changes occur in 1-13% of patients, often dose-dependent and reversible upon discontinuation. Elevated transaminases (ALT/AST >3x upper limit of normal) indicate hepatocellular injury, while rises in alkaline phosphatase or bilirubin point to cholestatic effects.[1][2]
Common Lab Patterns in Toxicity
- Mild elevations: ALT/AST 2-5x normal, seen early (days 3-7 of therapy), resolving without intervention.
- Severe cases: ALT/AST >10x normal or bilirubin >2x normal, linked to prolonged use (>14 days) or high doses (100 mg BID).
- Timing: Peaks around treatment week 2; monitors like weekly LFTs detect this before symptoms like jaundice emerge.[3]
Hepatic adverse events are more frequent in critically ill patients with comorbidities (e.g., sepsis, fatty liver), where tigecycline's biliary excretion (59% of dose) stresses impaired livers.[1]
Why Liver Changes Signal Toxicity
Tigecycline inhibits mitochondrial protein synthesis, disrupting hepatocyte energy production and causing oxidative stress. This leads to enzyme leakage from damaged cells. Unlike beta-lactams, tigecycline's broad biliary clearance amplifies risk in liver dysfunction—avoid or reduce dose if Child-Pugh C cirrhosis.[2][4]
FDA labeling notes hepatic events in 10% of trials, with post-marketing reports of acute liver injury (Hy's law cases: ALT >3x + bilirubin >2x).[5]
Monitoring and Risk Factors
Check baseline LFTs, then every 3-7 days. Stop if ALT >5x normal or symptoms (nausea, fatigue) appear. High-risk groups: elderly, obese, or those on hepatotoxins (e.g., statins). No genetic predictors identified, but trough levels >1 mcg/mL correlate with toxicity.[3][6]
Reversibility and Management
Most cases (80-90%) resolve within 1-4 weeks post-stop. Severe toxicity may need N-acetylcysteine or supportive care; rare fatalities in <0.1%.[2] Alternatives like eravacycline show lower hepatotoxicity (ALT rise <5%).[7]
Sources
[1]: Tigecycline Prescribing Information (FDA)
[2]: Hepatic Safety of Tigecycline: Meta-Analysis (Clin Infect Dis, 2010)
[3]: Tigecycline Pharmacokinetics in Liver Disease (J Antimicrob Chemother, 2009)
[4]: Drug-Induced Liver Injury Network (DILIN) Tigecycline Reports
[5]: FDA Adverse Event Reporting System (FAERS) Summary
[6]: Tigecycline Dosing in Hepatic Impairment (Antimicrob Agents Chemother, 2013)
[7]: Eravacycline vs Tigecycline Hepatic Safety (IgnITE Trial, Lancet Infect Dis, 2019)